Show simple item record

dc.contributor.authorM. Patel, Bhavik
dc.contributor.authorParatz, Jennifer D.
dc.contributor.authorC. See, Natalie
dc.contributor.authorJ. Muller, Michael
dc.contributor.authorRudd, Michael
dc.contributor.authorPaterson, David
dc.contributor.authorE. Briscoe, Scott
dc.contributor.authorUngerer, Jacobus P. J.
dc.contributor.authorMcWhinney, Brett C.
dc.contributor.authorA. Roberts, Jason
dc.date.accessioned2017-05-03T12:02:33Z
dc.date.available2017-05-03T12:02:33Z
dc.date.issued2012
dc.date.modified2014-06-12T23:44:20Z
dc.identifier.issn0163-4356
dc.identifier.doi10.1097/FTD.0b013e31824981a6
dc.identifier.urihttp://hdl.handle.net/10072/60159
dc.description.abstractBackground: Beta-lactams are first-line antibiotics for the management of superficial infections due to burn injury. There is sparse data available on therapeutic drug monitoring (TDM) in patients with burns in a ward setting. This study was conducted to evaluate the utility of a beta-lactam TDM program in a cohort of burn injury patients in a ward environment. Methods: Steady-state blood samples were collected immediately before a scheduled dose. The therapeutic concentration targets assessed were (1) free antibiotic concentrations exceeding the minimum inhibitory concentration (MIC; fT > MIC) and (2) free concentrations =4נMIC of the known or suspected pathogen (fT > 4נMIC). The duration of therapy was also assessed. Results: A total of 50 patients were included for TDM over a 12-month period. The mean (ᓄ) age was 49 ᠱ6 years. The mean percent total body surface area burn was 17 ᠱ3%. The mean serum creatinine concentration was 86 ᠲ0 孯le/L. Sixty percent of the patients did not achieve fT > MIC, and only 18% achieved the higher target of fT > 4נMIC. Although all the patients achieved a positive clinical outcome, the duration of antibiotic treatment was shorter in patients who achieved fT > MIC compared with those who did not (4.2 ᠱ.1 versus 5.3 ᠲ.3 days; P = 0.03). Conclusions: We found TDM to be a reliable intervention for burn injury patients in a ward environment. This study supports pharmacokinetic data that burns patients may be at risk of subtherapeutic dosing, which may prolong the duration of antibiotic therapy.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom160
dc.relation.ispartofpageto164
dc.relation.ispartofissue2
dc.relation.ispartofjournalTherapeutic Drug Monitoring
dc.relation.ispartofvolume34
dc.rights.retentionY
dc.subject.fieldofresearchPhysiotherapy
dc.subject.fieldofresearchAnalytical Chemistry
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode110317
dc.subject.fieldofresearchcode0301
dc.subject.fieldofresearchcode1115
dc.titleTherapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients—A One-Year Prospective Study
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorParatz, Jenny D.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record